Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 447

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer

Frasci, Giuseppe, Lorusso, Vito, Panza, Nicola, Comella, Pasquale, Nicolella, Gianpaolo, Bianco, Andrea, De Cataldis, Giuseppe, Iannelli, Annunziato, Bilancia, Domenico, Belli, Mario, Massidda, Bruno, Piantedosi, Francovito, Comella, Giuseppe, De Lena, Mario·2000·Journal of Clinical Oncology

Abstract

PURPOSE: To evaluate whether the addition of gemcitabine (G) to vinorelbine (V) improves survival and quality of life (QoL) among elderly patients with advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with NSCLC aged ≥ 70 years with advanced disease were randomly allocated to receive V 30 mg/m 2 on days 1 and 8 every 3 weeks or G 1,200 mg/m 2 + V 30 mg/m 2 on days 1 and 8 every 3 weeks. The estimated sample size was 120 patients per arm, but an interim analysis of survival was planned based on the first 60 patients per arm. RESULTS: In May 1999, the survival data were analyzed of 120 eligible patients (V group = 60; G + V group = 60) who had been randomized from June 1997 to February 1999. Forty-nine patients had stage IIIB disease, and 71 had stage IV. At a median potential follow-up of 14 months (range, 3 to 22 months), 93 patients had died (G + V group = 41; V group = 52). In the G + V group, median survival time was 29 weeks and projected 1-year survival was 30%; these values were 18 weeks and 13% in the V group. According to multivariate Cox analysis, the risk of death in the G + V arm compared with the V arm was 0.48 (95% confidence interval, 0.29 to 0.79; P < .01). Combination therapy was also associated with a clear delay in symptom and QoL deterioration. The overall response rates were 22% and 15% in the G + V and V groups, respectively. CONCLUSION: In elderly patients with NSCLC, G + V treatment is associated with significantly better survival than is V alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2000.18.13.2529

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 447

Metadata

Authors
Frasci, G., Lorusso, V., Panza, N., Comella, P., Nicolella, G., Bianco, A., De Cataldis, G., Iannelli, A., Bilancia, D., Belli, M., Massidda, B., Piantedosi, F., Comella, G., & De Lena, M.
Venue
Journal of Clinical Oncology
Published
2000-07-01
Volume
18
Issue
13
Pages
2529-2536
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1898736255
Cited by
447
References
15
FWCI
24.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2000.18.13.2529
The paper
Frasci, G., Lorusso, V., Panza, N., Comella, P., Nicolella, G., Bianco, A., De Cataldis, G., Iannelli, A., Bilancia, D., Belli, M., Massidda, B., Piantedosi, F., Comella, G., & De Lena, M. (2000). Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.13.2529

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.